70 related articles for article (PubMed ID: 716322)
1. [Phenotypic changes in acetylation in tumor patients].
Bulovskaia LN; Blinov NN; Simonov NN; Krupkin RG; Kolosov AI
Vopr Onkol; 1978; 24(10):76-9. PubMed ID: 716322
[TBL] [Abstract][Full Text] [Related]
2. Acetylator phenotype in patients with lung carcinoma--a negative report.
Burgess EJ; Trafford JA
Eur J Respir Dis; 1985 Jul; 67(1):17-9. PubMed ID: 4054252
[TBL] [Abstract][Full Text] [Related]
3. [Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
Skretowicz J; Polakowski P; Jeromin L; Zasada M; Szymańska J; Krajewska B
Med Pr; 1988; 39(4):241-5. PubMed ID: 3237058
[TBL] [Abstract][Full Text] [Related]
4. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation.
Oyama T; Kawamoto T; Mizoue T; Yasumoto K; Kodama Y; Mitsudomi T
Anticancer Res; 1997; 17(1B):577-81. PubMed ID: 9066583
[TBL] [Abstract][Full Text] [Related]
5. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
[TBL] [Abstract][Full Text] [Related]
6. N-acetyltransferase phenotype of patients with cancer of the larynx.
Drózdz M; Gierek T; Jendryczko A; Pilch J; Piekarska J
Neoplasma; 1987; 34(4):481-4. PubMed ID: 3658048
[TBL] [Abstract][Full Text] [Related]
7. Acetylation phenotype in colorectal carcinoma.
Ilett KF; David BM; Detchon P; Castleden WM; Kwa R
Cancer Res; 1987 Mar; 47(5):1466-9. PubMed ID: 3815349
[TBL] [Abstract][Full Text] [Related]
8. [Acetylation phenotype in patients with lung cancer].
Cofta S; Lowicki Z; Młynarczyk W
Pneumonol Alergol Pol; 1995; 63(7-8):407-9. PubMed ID: 8520558
[TBL] [Abstract][Full Text] [Related]
9. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.
Grant DM; Mörike K; Eichelbaum M; Meyer UA
J Clin Invest; 1990 Mar; 85(3):968-72. PubMed ID: 2312737
[TBL] [Abstract][Full Text] [Related]
10. [Acetylation polymorphism in lung cancer].
Laredo Quesada JM; Jara Sánchez C; Benítez Rodríguez J; Fernández Gundín MJ; Vargas Castrillón E; Muñoz González JJ; Llerena Ruiz A; Cobaleda Polo J; Pérez-Manga G
An Med Interna; 1991 Feb; 8(2):66-8. PubMed ID: 1893005
[TBL] [Abstract][Full Text] [Related]
11. [Acetylation phenotype in Graves' disease].
Górnik W; Syrenicz A; Gawrońska-Szklarz B; Wójcicki J
Pol Tyg Lek; 1989 Aug 7-14; 44(32-33):743-5. PubMed ID: 2641798
[TBL] [Abstract][Full Text] [Related]
12. N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.
Siegmund W; Franke G; Wulkow R; Hanke W; Thonack R
Int J Clin Pharmacol Ther Toxicol; 1991 Dec; 29(12):469-73. PubMed ID: 1813431
[TBL] [Abstract][Full Text] [Related]
13. Ecogenetic studies of drug acetylation in man and rats.
Dubbels R; Khoory R; Schloot W
Acta Anthropogenet; 1981; 5(2):111-8. PubMed ID: 7271997
[TBL] [Abstract][Full Text] [Related]
14. Correlation between N-acetyltransferase activities in uroepithelia and in vivo acetylator phenotype.
Pink JC; Messing EM; Reznikoff CA; Bryan GT; Swaminathan S
Drug Metab Dispos; 1992; 20(4):559-65. PubMed ID: 1356735
[TBL] [Abstract][Full Text] [Related]
15. Acetylation phenotype is not associated with breast cancer.
Ilett KF; Detchon P; Ingram DM; Castleden WM
Cancer Res; 1990 Oct; 50(20):6649-51. PubMed ID: 2208127
[TBL] [Abstract][Full Text] [Related]
16. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs.
Palamanda JR; Hickman D; Ward A; Sim E; Romkes-Sparks M; Unadkat JD
Drug Metab Dispos; 1995 Apr; 23(4):473-7. PubMed ID: 7600914
[TBL] [Abstract][Full Text] [Related]
17. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
[TBL] [Abstract][Full Text] [Related]
18. [Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer].
Orzechowska-Juzwenko K; Wiela-Hojeńska A; Milejski P; Cieślińska A; Hudziec P; Adamska M
Przegl Lek; 1997; 54(2):103-6. PubMed ID: 9198818
[TBL] [Abstract][Full Text] [Related]
19. Immunological evidence for N-acetyltransferase isozymes in the rabbit.
Reeves PT; Kinnear BF; Minchin RF; Ilett KF
Mol Pharmacol; 1991 Jan; 39(1):42-8. PubMed ID: 1987451
[TBL] [Abstract][Full Text] [Related]
20. [Determination of the phenotype of N-acetyltransferase activity].
Bulovskaia LN; Borisenko GN; Drobachenko OA; Kurbatova GP; Ivanova VV
Lab Delo; 1990; (10):28-30. PubMed ID: 1704451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
